Neuroleptic malignant syndrome: need for early diagnosis and therapy by Khan, Humaira M. et al.
J Ayub Med Coll Abbottabad 2006;18(1) 
 
NEUROLEPTIC MALIGNANT SYNDROME: NEED FOR EARLY 
DIAGNOSIS AND THERAPY 
Humaira M. Khan, Nadir A. Syed, Mughis Sheerani, Bhojo Khealani, Ayeesha Kamal, 
Mohammad Wasay 
Department of Medicine, Section of Neurology, The Aga Khan University, Karachi 
Background: Neuroleptic Malignant Syndrome (NMS) is a medical entity that has received little 
attention in the clinical settings in Pakistan. The aim of our study was to review the predisposing 
factors, outcomes and characteristics of in-patients diagnosed with NMS. Methods: We 
performed a retrospective chart review of all cases (age > 15 years) at a tertiary care center in 
Karachi between January 01, 1990 and November 30, 2001, diagnosed using ICD 10 coding.  Data 
was collected using a standardized data entry form and statistical analysis was performed using 
Epi Info 6, Version 6.02. Results: There were a total of 20 patients diagnosed with NMS (11 male 
and 9 female) in our study with a mean age of 46.6±15.9 years. Haloperidol was the most 
frequently responsible neuroleptic. Of the 18 patients on a neuroleptic, most developed NMS after 
8 weeks of therapy. There were 5 mortalities all of which were associated with septic shock. 
Fourteen patients recovered completely from the episode and did not have any neurologic 
sequelae. Conclusions: NMS is an important preventable clinical entity. Early diagnosis and 
judicious use of antipsychotics is warranted to prevent mortality and heightened morbidity.  
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INTRODUCTION  
Neuroleptic Malignant Syndrome (NMS) is a rare but 
potentially fatal idiosyncratic reaction associated with 
the use of antipsychotics. It has been seen to occur 
secondary to the use of a range of neuroleptics 
(typical and atypical) as well as various non-
neuroleptic medications1. It can also occur following 
sudden discontinuation of anti-Parkinsonian 
medications2-4. NMS is characterized by 
hyperthermia, extra-pyramidal rigidity, autonomic 
dysfunction and altered consciousness. Morbidity and 
mortality in NMS is most often secondary to 
cardiopulmonary and renal complications. Early 
diagnosis and cessation of neuroleptics are associated 
with a better outcome.  
NMS remains a medical entity that has 
received little focus in the clinical settings in 
Pakistan. The only study performed in Pakistan on 
NMS reported 7 cases in Karachi in 1986 5. The aim 
of our study, therefore, was to review the clinical 
features, pharmacologic variables, risk factors, 
complications and outcome of patients with NMS at a 
tertiary care center in Pakistan in order to better 
define the characteristics of NMS in the local 
therapeutic and diagnostic environment. We believe a 
scrutiny of the local pattern of NMS would enhance 
our ability to diagnose and treat NMS more 
effectively. 
MATERIAL AND METHODS  
We carried out a retrospective chart review of all 
cases (age > 15 years) presenting to The Aga Khan 
University Hospital, Karachi, between January 01, 
1990 and November 30, 2001 classified as having a 
definite diagnosis of NMS at discharge from hospital 
using ICD 10 coding. Of the 25 cases identified on 
initial search, 20 cases were included for final 
analysis as there was insufficient clinical data for 
adequate review in 5 cases.  
Diagnosis of NMS was based on previously 
validated criteria 6. Autonomic dysfunction was 
considered in terms of high systolic (>140 mm Hg) or 
diastolic (>100 mm Hg) blood pressure (BP), labile 
BP (variability more than 30 mmHg systolic or more 
than 20 mmHg diastolic at different readings), 
tachycardia (≥ 100 beats per minute), tachypnea (≥ 
25 breaths per minute), prominent diaphoresis and 
incontinence of urine and/or feces.  
A standardized data entry form was 
developed and the data collected included 
demographics, signs and symptoms at presentation, 
known risk factors for NMS, primary psychiatric 
diagnosis, details of neuroleptic use, concomitant use 
of anticholinergics, tricyclic antidepressants (TCA), 
selective serotonin receptor inhibitors (SSRI), and 
lithium, laboratory abnormalities, therapeutic 
interventions, complications during hospital stay and 
outcome characterized by mortality or neurologic 
sequelae. Laboratory abnormalities evaluated 
included degree of leukocytosis and elevations of 
creatinine phosphokinase (CPK) [>200 IU/L]. Serial 
values of CPK were noted whenever available.  
Therapeutic interventions for the management of 
NMS were noted, including supportive therapy, 
discontinuation of neuroleptic use, administration of 
dopaminergic agents or muscle relaxants. Functional 
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outcome of NMS patients was assessed using Rankin 
Score 7. 
Extra-pyramidal signs and symptoms noted 
included rigidity, choreiform movements, tremor, 
oculogyric crisis, dyskinetic movements, flexor-
extensor posturing, trismus, sialorrhea, retrocollis, 
opisthotonus and festinating gait. Chronological 
order of symptoms (temporal sequence of appearance 
of autonomic instability, extra-pyramidal symptoms, 
hyperthermia, and altered consciousness) was 
assessed when symptoms had developed over 2 or 
more days. Past history was also assessed to include 
history of catatonia, mania or other affective disorder, 
decreased oral intake in the week preceding symptom 
development, significant weight loss, a previous 
episode of NMS, history of substance abuse, 
possibility of deliberate overdose or self-medication, 
neurologic disease and previous treatment with 
electro-convulsive therapy (ECT). Data analysis was 
carried out using Epi Info 6, Version 6.02 (A Word 
Processing, Database and Statistics Program for 
Public Health, Centers for Disease Control and 
Prevention (CDC), USA and World Health 
Organization, Geneva, Switzerland).  
RESULTS  
There were 11 male and 9 female patients of NMS in 
our study with a mean age of 46.6±15.9 years (range: 
17 to 73 years). There were 5 patients over 60 years 
of age and 3 were less than 25 years old. Table 1 
summarizes the clinical features of all 20 patients. 
Affective disorder was the primary psychiatric 
diagnosis in 12 of our patients, 9 of whom were 
documented to have psychotic features. The other 
major psychiatric diagnosis was schizophrenia (n=4), 
including catatonic and undifferentiated types, while 
1 patient had schizoaffective disorder. Three patients 
were not documented to suffer any psychiatric 
illness. Nineteen patients were admitted through the 
Emergency Room (ER).  
Neuroleptics prescribed included oral and 
depot preparations of both high and low potency anti-
psychotics. Depot preparations had been used in 5 
(25%) of our patients, intramuscular injections of 
neuroleptics in 9 (45%) patients and 5 (25%) patients 
received a combination of an oral and injectable 
antipsychotics medication. Haloperidol was the most 
frequently responsible drug (9 of 16 patients on 
neuroleptics). Eight patients were using more than 2 
neuroleptics concomitantly. Duration of neuroleptic 
use is summarized in Figure 1. Of the 18 patients on 
neuroleptics, 60% developed NMS after 8 weeks of 
therapy. Two patients were not on neuroleptics but 
had abrupt discontinuation of their anti-parkinsonian 
drug(s) only. Recent (<2 weeks) addition of a 
neuroleptic was documented in 6 patients. Six 
patients had experienced a recent (<1 week) increase 
in dose of the neuroleptic and 3 patients had 
experienced both a recent increase in dose of 
neuroleptic as well as addition of another neuroleptic 
to their treatment regimen. Only one patient had been 
given neuroleptics for the first time and developed 
symptoms of NMS within 24 hours.  
Figure 2 shows the time course for 
development of the symptoms of NMS. Most patients 
developed symptoms slowly, while 8 patients (40%) 
developed full-blown NMS over a period of 3 days 
only. Six of the patients who had developed 
symptoms rapidly (≤3 days) were diagnosed NMS 
within 24 hours of presentation. In their case CPK 
was >1000 IU/l at admission, while in the other 2 
cases, CPK was normal or only slightly elevated. In 2 
cases, diagnosis was established in >1 week: one was 
an elderly patient with mild symptoms and no 
documented fever; the other had Parkinson’s disease 
and had presented in septic shock following sudden 
withdrawal of anti-Parkinsonian medications. 
All patients were managed in the special 
care unit. Laboratory findings are summarized in 
Table 2. Four patients developed multi-organ failure 
in association with sepsis. One patient developed 
acute renal failure due to hypovolemic shock; 1 
developed rhabdomyolysis with acute renal failure; 2 
developed aspiration pneumonia. In addition to 
supportive treatment, dopamine agonists were used in 
12 patients, bromocriptine in 11 cases and anti-
cholinergics were given to 9 patients. Dantrolene was 
used in 2 patients and diazepam in 3 patients.  EEG 
was done in 4 patients, 2 of which were consistent 
with metabolic encephalopathy while the other 2 
were reported normal. 
The mean number of days for resolution of 
NMS following cessation of neuroleptics was 17.55 ± 
9.47 days (range: 6-30 days). Table 3 shows the 
duration of symptoms of NMS in survivors following 
cessation of neuroleptic(s). There were 5 mortalities 
all of which were associated with septic shock. 
Fourteen patients recovered completely from the 
episode and did not have neurologic sequelae or 
cognitive impairment after recovery or on follow up. 
One patient was shifted to another hospital and was 
lost to follow up. Of the 4 Parkinsonian patients, only 
one recovered fully (Rankin score = 0). Interestingly, 
7 of the 20 patients were re-challenged with 
neuroleptics and one with lithium; however, no 
relapse during hospital stay was documented in these 
patients.  
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Figure 1. Total duration of neuroleptic use (n=15) 
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Figure 2. Time course for development of 
symptoms of NMS (n=20) 
 
 
 
 
 
Table 1. Clinical Features of Patients with 
Neuroleptic Malignant Syndrome (NMS) (n=20) 
 Frequency 
Feature N % 
Clinical   
Tmax
> 380 C 19 95 
Afebrile 1 5 
Autonomic Dysfunction
Hypertension 13 65 
Labile BP 4 20 
Tachycardia >100 bpm 14 70 
Tachypnea >25 
resp/min 
8 40 
Diaphoresis 2 10 
Incontinence 5 25 
Total  20 100 
EPS
Rigidity 17 85 
Tremor 2 10 
Dyskinetic movements 2 10 
Flexor-extensor 
posturing 
4 20 
Sialorrhea 3 15 
Retrocollis 11 55 
Total  20 100 
Altered consciousness
Confused but 
verbalizing 
2 10 
Unintelligible sounds 8 40 
Coma 9 45 
Total 19 95 
BP= blood pressure, bpm= beats per minute, resp/min= breaths per 
minute, EPS= Extrapyramidal signs, 
Table 2: Biochemical Characteristics of Patients 
with Neuroleptic Malignant Syndrome (NMS) 
  Frequency 
Feature Total N % 
Labs:    
CPK (IU/L) 16 9 56 
>1000  6 38 
400-1000    
200-400  0 0 
<200  1 6 
Total Abnormal  15 93.8 
WBC (cell/ul)  19   
>15000  8 42 
10000-15000  6 32 
<10000  5 26 
Total Abnormal  14 73.7 
Lumbar Puncture (LP) 10   
High protein (moderate elevation)  2 20 
High cells (minimal), with normal 
protein  
 1 10 
Total Abnormal  3 30 
Renal Function Tests Abnormal    20 10 50 
Liver Function Tests (LFT) 
Abnormal 
14 4 28.6 
0
2
4
6
8
10
<24 hours <2 weeks 2-4 weeks 4-8 weeks >8 weeks 
0
1
2
3
4
5
Table 3: Duration of symptoms of NMS in 
survivors following cessation of neuroleptics 
Duration of syndrome Frequency % 
< 7 days 2 18.2 
7-14 days 2 18.2 
14-21 days 3 27.3 
> 21 days 4 36.4 
Total 11 100 
DISCUSSION  
Virtually all neuroleptics are capable of inducing 
NMS, including the newer atypical antipsychotics. 
NMS should feature in the differential diagnosis of 
any patient receiving a neuroleptic who develops 
fever or rigidity. In our study, Haloperidol was by far 
the most commonly responsible antipsychotic 
(56.3%) for NMS in the local population. One patient 
was receiving 4 different oral and depot preparations 
of high potency neuroleptics in combination with one 
low potency one. Use of newer (atypical) 
antipsychotic medications instead of haloperidol may 
be associated with lower rates of NMS and extra-
pyramidal symptoms 8. 
Factors that have been suggested as being 
more provocative include the rate of introduction of 
neuroleptics, the use of depot preparations, a 
preceding attack of NMS, and the concomitant use of 
other drugs, in particular, lithium9-13. Depot 
preparations, intramuscular injections of anti-
pscyhotics and combinations of these with oral 
preparations were being used by 25%, 45% and 25% 
of our patients, respectively. Concomitant use of 
lithium was seen in only one patient in our study. 
High potency neuroleptics in combination with a 
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tricyclic antidepressant were being prescribed in 4 
others. 
Our results show that where the full-blown 
syndrome developed over 3 days or less, no difficulty 
in making a diagnosis of NMS was encountered 
especially when supported by high CPK levels. In 
NMS, the rise in CPK is often significant, sometimes 
reaching levels above 100,000 IU per liter (IU/l). We 
noted a level of >100,000 IU/l in one patient. 
However, high CPK values alone should not be 
regarded as diagnostic markers for NMS.14 Prominent 
increases have been found in upwards of 70% of 
patients taking neuroleptics who become pyrexial due 
to infection,15 and some 30% of medically ill patients 
(not receiving neuroleptics) show a similar, albeit 
less exaggerated, rise in CPK.16 Furthermore, 
asymptomatic CPK elevations can occur in patients 
with psychotic disorders, whether clinically stable or 
acutely ill, following oral treatment with typical or 
atypical neuroleptics.17-19 These findings suggest the 
need for a high index of suspicion for NMS in 
patients whose clinical findings evolve subacutely.  
Quantitative CPK values were available for 
3 of the 4 Parkinson’s disease patients. CPK levels 
were >1000 IU/l on admission in all 3 patients. This 
trend for the Parkinson’s subgroup is interesting 
because in these patients CPK may perhaps play a 
role in the early diagnosis of NMS. Among the 4 
Parkinson’s disease patients, there were 3 mortalities; 
only one recovered fully (Rankin score = 0). Our 
results are consistent with those of other studies 20,21 
where it has been shown that Parkinsonian patients in 
particular have very poor prognosis. These findings 
suggest the need for particularly aggressive 
monitoring and early intervention in case of NMS 
occurring in patients suffering from Parkinson’s 
disease. 
Velamoor et al22 found that of all order 
implications, 70.5% were consistent with the 
sequence of mental-status changes followed by 
rigidity, hyperthermia, and autonomic dysfunction. 
Changes in either mental status or rigidity were the 
initial manifestations of NMS in 82.3% of cases with 
a single presenting sign and were significantly more 
likely to be observed before hyperthermia and 
autonomic dysfunction. One of our patients did not 
develop fever at any time throughout the episode of 
NMS. Extrapyramidal features and autonomic 
instability, however, were present in this patient. 
Several authors have reported such variants of NMS 
which suggests that NMS is a spectrum disorder23-26 
and a number of cases of NMS with no rise in 
temperature or negligible temperature elevations have 
been described. This underlines the importance of 
looking at the complete clinical picture rather than 
relying on individual signs and symptoms meeting 
arbitrarily fixed thresholds for disease.  
Agitation and dehydration are known to 
make independent contributions to risk12,13,23,25,27. Six 
of our patients had concurrent medical illnesses 
leading to agitation and dehydration. Two others had 
refused oral intake for 1 and 5 days respectively. 
Both developed symptoms within the next 24 hours. 
Two of our patients had received ECT within the 
previous year; in one case, the last cycle of ECT had 
been completed 2 weeks before symptoms began. 
Our findings are supported by a case-control study of 
NMS patients where ECT emerged as a significant 
risk factor 27. 
Most frequently considered differentials in 
our patients were Central Nervous System (CNS) 
infections (30%) and neuroleptic-induced dystonia or 
Parkinsonism (20%). CNS infection which can 
present with fever and altered consciousness can pose 
a special problem. An LP can be particularly helpful 
in such cases. Other infections can often co-exist with 
NMS and clinicians should not hesitate to make a 
diagnosis of NMS and a concomitant infection. 
Infection may predispose patients to NMS by causing 
dehydration and agitation. Conversely, NMS may 
create a setting for infection as a result of respiratory 
compromise, immobility, and urinary catheterization. 
It is important that clinicians are able to make a 
diagnosis of NMS in the presence of a non-CNS 
infection as the two may often co-exist. Attributing 
the patients’ symptoms to sepsis in this setting could 
be a costly mistake as delays in instituting 
appropriate therapy may result. 
In the management of NMS, the most 
effective measures include prompt recognition, 
withdrawal of neuroleptic medication, and transfer to 
an intensive/special care unit, with attention to 
hydration, fever reduction, sedation with 
benzodiazepines, if indicated, and control of rigidity 
with bromocriptine or dantrolene.  
CONCLUSION 
NMS is an important preventable clinical entity. 
Judicious use of antipsychotics including cessation of 
rapid neuroleptization, better hydration of patients 
during titration of medication, avoiding use of 
multiple anti-psychotics simultaneously, and use of 
non-depot neuroleptics whenever possible, is 
warranted. Use of the newer atypical agents may also 
be considered. Early diagnosis can prevent both 
morbidity and mortality therefore heightened clinical 
awareness with regard to its varied presentation and 
special high risk groups (the elderly and Parkinson’s 
disease patients) and careful investigation to rule out 
alternative diagnoses are important.  
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